The U.S. Rx-to-OTC market has grown into a $13,807 million ($13.8 billion) market, according to 2021 estimates by leading medical market researcher Kalorama Information in the new report The Market for Rx-to-OTC Switches, 8th Edition. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness […]
Not since the Swine Flu epidemic of 2009 has there been this amount of emphasis on vaccines and vaccine development. This new infectious disease threat with no anti-viral, nor vaccine is causing significant concern among healthcare providers, governments and the public. Last-resort measures such as school closings and curfews in place in the United States […]
News of an approval of a biosimilar for a major Roche cancer drug is, we think, evidence that U.S. biosimilars are a growth market opportunity. At the same time, the approval is a growth limiter for booming cancer drug markets. Pfizer Inc confirmed Friday that the the FDA approved its biosimilar to Avastin. Pfizer’s Zirabev […]
Email Us: Customer Service
Phone (US): 703-778-3080
Fax: 703-778-3081
